Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

Yu Sawada(Shizuoka Cancer Center), Tetsuya Nakatsura(Unknown), Toshimitsu Kuronuma(Shizuoka Cancer Center), Shoichi Mizuno(Shizuoka Cancer Center), Kohei Nakachi(National Cancer Center Hospital East), Toshiaki Yoshikawa(Aichi Cancer Center), Naoto Gotohda(Shizuoka Cancer Center), Daisuke Nobuoka(Fukuyama City Hospital), Junji Furuse(Kanagawa Prefectural Hospital Organization), Hiroshi Ishii(Chiba Cancer Center), Masaru Konishi(Shizuoka Cancer Center), Kenji Yamao(Aichi Cancer Center), Toshio Nakagohri(Tokai University), Shinichiro Takahashi(Shizuoka Cancer Center), Tadatoshi Takayama(Nihon University), Hirofumi Shirakawa(Shizuoka Cancer Center), Yutaka Motomura(Shizuoka Cancer Center), Taira Kinoshitá(National Cancer Center Hospital East), Katsuhiko Uesaka(Shizuoka Cancer Center)
Clinical Cancer Research
May 10, 2012
10.1158/1078-0432.ccr-11-3044
Cited by 299

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749